Does tranexamic acid lead to changes in MRI measures of brain tissue health in patients with spontaneous intracerebral haemorrhage? Protocol for a MRI substudy nested within the double-blind randomised controlled TICH-2 trial. Issue 2 (3rd February 2018)

• Record Type: Journal Article
• Authors: Dineen, Rob A; Pszczolkowski, Stefan; Flaherty, Katie; Law, Zhe K; Morgan, Paul S; Roberts, Ian; Werring, David J; Salman, Rustam Al-Shahi; England, Tim; Bath, Philip M; Sprigg, Nikola
• Is Part Of: BMJ open. Volume 8:Issue 2(2018)
• Publication Date: 2018-02-03
• Subjects: hyperacute primary intracerebral haemorrhage -- tranexamic acid -- magnetic resonance imaging -- diffusion weighted imaging -- perihaematomal oedema; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2017-019930
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objectives: To test whether administration of the antifibrinolytic drug tranexamic acid (TXA) in patients with spontaneous intracerebral haemorrhage (SICH) leads to increased prevalence of diffusion-weighted MRI-defined hyperintense ischaemic lesions (primary hypothesis) or reduced perihaematomal oedema volume, perihaematomal diffusion restriction and residual MRI-defined SICH-related tissue damage (secondary hypotheses). Design: MRI substudy nested within the double-blind randomised controlled Tranexamic Acid for Hyperacute Primary Intracerebral Haemorrhage (TICH)-2 trial (ISRCTN93732214 ). Setting: International multicentre hospital-based study. Participants: Eligible adults consented and randomised in the TICH-2 trial who were also able to undergo MRI scanning. To address the primary hypothesis, a sample size of n=280 will allow detection of a 10% relative increase in prevalence of diffusion-weighted imaging (DWI) hyperintense lesions in the TXA group with 5% significance, 80% power and 5% imaging data rejection. Interventions: TICH-2 MRI substudy participants will undergo MRI scanning using a standardised protocol at day ~5 and day ~90 after randomisation. Clinical assessments, randomisation to TXA or placebo and participant follow-up will be performed as per the TICH-2 trial protocol. Conclusion: The TICH-2 MRI substudy will test whether TXA increases the incidence of new DWI-defined ischaemic lesions or reduces perihaematomal oedema or final ICH lesion volume in the context of SICH. Ethics and dissemination: The TICH-2 trial obtained ethical approval from East Midlands - Nottingham 2 Research Ethics Committee (12/EM/0369) and an amendment to allow the TICH-2 MRI sub study was approved in April 2015 (amendment number SA02/15). All findings will be published in peer-reviewed journals. The primary outcome results will also be presented at a relevant scientific meeting. Trial registration number: ISRCTN93732214 ; Pre-results.